JNJ Related Analyst EPS View
-
Jefferies Trims Estimates, Ups PT on Johnson & Johnson (JNJ) Post Q1
-
Goldman Maintains Sell on Johnson & Johnson (JNJ); Drug Business Spin Still Unlikely
-
Refinancing of Debt Helps Alkermes (ALKS) Save Cash, MKM Reiterates Buy, Raises PT
-
Wedbush Reiterates an 'Outperform' on Medivation (MDVN); Raising PT on Early Approval
-
Maxim Upgrades Dendreon (DNDN) as the Street is 'Too Bearish' Ahead of Q2 Results
-
RBC Capital Negative on Dendreon (DNDN) Ahead of Q2 Results
-
Q2 Preview: Eyes on J&J's (JNJ) New CEO Gorsky Into Print, Conference Call
-
Wedbush Reiterates an 'Outperform' on Medivation (MDVN); Raising PT and 2013 Estimates
-
Auriga Maintains a 'Buy' on Perrigo Co. (PRGO); Accumulate Shares on Weakness
-
UBS Maintains a 'Buy' on Johnson & Johnson (JNJ); Held Back By Slow EPS Growth
-
Q1 Preview: Bellwether Johnson & Johnson (JNJ) has New CEO, Patent Expiration on Its Plate
Back to JNJ Stock Lookup
